Soligenix: FDA OKs Phase 2 for Ulcers in Behçet's Disease

 Pipeline Expansion of Novel Innate Defense Regulator Technology

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial entitled, "Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behçet's Disease." The study is designed to evaluate the safety and efficacy of SGX945 (dusquetide) and is expected to begin patient enrollment in the second half of 2024.

https://www.prnewswire.com/news-releases/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-dusquetide-in-the-treatment-of-aphthous-ulcers-in-behcets-disease-302001677.html